106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 44-45

106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

Background

Despite modern HER2-directed treatment options, relevant recurrence risk persists in patients with extensive local disease and/or lack of pathologic complete response (pCR) to neoadjuvant therapy. Neratinib is approved in Europe for extended adjuvant therapy in adult patients with HER2-positive (HER2+)/hormone receptor–positive (HR+) early breast cancer who completed adjuvant trastuzumab-based therapy less than 1 year ago. In this population, the phase 3 ExteNET study (NCT00878709) demonstrated an absolute 5.1% improvement in 5-year invasive disease-free survival (iDFS) with neratinib compared with placebo (90.8% vs 85.7%; HR, 0.58; 95% CI, 0.41-0.82). Exploratory post hoc analyses demonstrated a more pronounced benefit in patients who don’t have a pCR and/or in those completing neratinib therapy. Diarrhea was the most common adverse effect (AE) in the neratinib arm (39% grade 3 without primary diarrhea prophylaxis). ELEANOR (NCT04388384) is the first noninterventional study of the real-world use and management of neratinib given after the current adjuvant standard of care in patients with HER2+/HR+ early breast cancer in Germany, Austria, and Switzerland.

Materials and Methods

A total of 300 patients diagnosed with HER2+/HR+ early breast cancer were planned to be enrolled in accordance with the European Medicines Agency/Swissmedic product specifications. The primary objective is to assess patient adherence to neratinib (ie, ≥ 75% of prescribed treatment days). Secondary objectives focus on patient and tumor characteristics, pretreatment and neratinib treatment details, effectiveness, safety, and health-related quality of life. Results of the preplanned interim analysis based on 300 enrolled patients observed for a minimum of 3 months are reported.

Results

At the data cut-off on August 5, 2023, 286 patients qualified for the main analysis set and 288 patients for the safety analysis set, respectively. Median age at inclusion was 52.0 years, 73.4% (210/286) of patients were at increased risk of disease recurrence having AJCC stage I or higher or N+ or non-pCR after neoadjuvant treatment. Overall, 37.4% (107/286) and 31.8% (91/286) of patients received adjuvant/post-neoadjuvant trastuzumab monotherapy or trastuzumab/pertuzumab, respectively, and 22.4% (64/286) of patients received post-neoadjuvant trastuzumab-emtansine (T-DM1). In patients who had non-pCR following neoadjuvant treatment, 55.4% (62/112) received post-neoadjuvant T-DM1. Dose escalation strategy (neratinib starting dose < 240 mg) was used in 44.4% (128/288) of patients, and 86.8% (250/288) of patients received diarrhea prophylaxis. AEs were consistent with the known safety profile of neratinib with incidence of grade 3 or higher diarrhea by worst grade less common in patients starting on a lower dose of neratinib (15.6% vs 23.8%). At the time of this preplanned interim analysis with an estimated median observation time for disease-free survival of 14.0 months, 6 patients (6/286, 2.1%) had experienced a relapse and one patient died since starting neratinib treatment, resulting in a 12-month DFS rate of 97.4% (95% CI, 94.6-98.7).

Conclusion

This preplanned interim analysis provides data on the use of neratinib in a contemporary cohort of predominantly higher-risk patients and after completion of pertuzumab- and T-DM1-containing adjuvant regimens in routine clinical practice. Preliminary effectiveness data appears to be consistent with previous data and the integration of treatment management strategies such as diarrhea prophylaxis and neratinib dose escalation were shown to enhance treatment tolerability.

Articles in this issue

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status
48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer
52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy
54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial
54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?
59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?
60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations
60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations
61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?
61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?
63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q
63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.